4.6 Article

The Brief Negative Symptom Scale: Psychometric Properties

期刊

SCHIZOPHRENIA BULLETIN
卷 37, 期 2, 页码 300-305

出版社

OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbq059

关键词

schizophrenia; negative symptoms; rating scale

资金

  1. Pfizer
  2. Organon
  3. AstraZeneca
  4. Wyeth
  5. Bristol Myers Squibb
  6. Cephalon
  7. Lilly
  8. Abbott
  9. Boehinger Ingelheim
  10. Solvay
  11. Sanofi Aventis
  12. Otsuka
  13. Lundbeck
  14. Novartis
  15. GlaxoSmithKline

向作者/读者索取更多资源

The participants in the NIMH-MATRICS Consensus Development Conference on Negative Symptoms recommended that an instrument be developed that measured blunted affect, alogia, asociality, anhedonia, and avolition. The Brief Negative Symptom Scale (BNSS) is a 13-item instrument designed for clinical trials and other studies that measures these 5 domains. The interrater, test-retest, and internal consistency of the instrument were strong, with respective intraclass correlation coefficients of 0.93 for the BNSS total score and values of 0.89-0.95 for individual subscales. Comparisons with positive symptoms and other negative symptom instruments supported the discriminant and concurrent validity of the instrument.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据